Technical Name |
使用G72蛋白質與SLC7A11 mRNA作為生物標記來診斷阿茲海默氏症的方法 |
Project Operator |
Chang Gung Medical Foundation |
Project Host |
林潔欣 |
Summary |
The present technology provides a method for diagnosing Alzheimer's disease, including the following steps: detecting a blood sample taken from a human subject suspected of having Alzheimer's disease,the biomarker level is selected from G72 protein level, SLC7A11 mRNA expression level,a combination of the two,compared with a preset standard, wherein if the detected biomarker level in the blood sample is higher than the preset standard, the Individual humans are thought to have Alzheimer's disease.
|
Scientific Breakthrough |
Current research on biomarkers of Alzheimer's disease has focused on known pathological substrates, such as amyloid plaquesneurofibrillary tangles, but has not yet produced a usefuldefinitive diagnostic method. The current technology is based on new mechanisms of DAAO activator (DAOA,named G72)cystine/glutamate antiporter system xc-. The combination of G72SLC7A11 (xCT) ΔCT determined a favorable AUC between patients with Alzheimer's diseasehealthy controls. There has been no similar product on the market.
|
Industrial Applicability |
The number of patients suffering from Alzheimer's disease is increasing rapidly around the world. However, there is still a lack of simpleaccurate diagnostic tools, therefore hampering its early diagnosistreatmentconsequently increasing family burdensocial cost. The current technology uses peripheral blood to preciselyeasily diagnose Alzheimer's disease. Due to its fast, easy,low-invasive advantage, it can not only generate huge industrial value but thereafter also reduce the social cost. Our technique has obtained domesticinternational patents.
|
Matching Needs |
1.欲媒合之產業領域:生技醫藥。2.欲媒合項目:技術合作、技術轉移、生產製造、投資合作。
|
Keyword |
Alzheimer’s disease G72 protein SLC7A11 mRNA Biomarker D-amino acid oxidase (DAAO) activator (DAOA) Dementia Peripheral blood NMDA Cognitive aging Diagnostic tool |
Notes |
|